



124 10/25/94

12E

\$2
02/08/95
A

PATENT
Attorney Docket No. 2481-1403-00

IN THE UNITED STATES PATENT AND TRADEMARK OFFICE

In re Application of:

ULRICH STACHE et al.

Serial No.: 08/310,791

Filed: September 29, 1994

Group Art Unit: 1204

Examiner: [Redacted]

For: CORTICOID-17, 21-DICARBOXYLIC ESTERS AND CORTICOSTEROID
17-CARBOXYLIC ESTER 21-CARBONIC ESTERS, PROCESSES FOR THEIR
PREPARATION AND PHARMACEUTICALS CONTAINING THESE COMPOUNDS

Honorable Commissioner of Patents
and Trademarks
Washington, D.C. 20231

Sir:

INFORMATION DISCLOSURE STATEMENT UNDER 37 C.F.R. § 1.97(b)

Under 37 C.F.R. §§ 1.56 and 1.97(b), applicants submit the documents listed on the attached form PTO 1449. This Information Disclosure Statement is being filed within three months of the filing date of the above-referenced application. Copies of the listed documents are attached.

Applicants respectfully request that the Examiner consider the listed documents and indicate that they were considered by making appropriate notations on the attached form.

The following is a concise statement of relevance of the non-English language documents:

1. European Patent Application 0 470 617 A2 relates to 17-substituted corticoid-17-alkyl carbonates, methods of their preparation, and pharmaceutical compositions containing them; and

94 DEC - 1 PM
[Redacted]

2. Staab et al., Chem. Ber. 95:1284-97 (1962) relates to methods of synthesizing carboxylic acid esters using imidazolides.

This submission does not represent that a search has been made or that no better art exists and does not constitute an admission that each or all of the listed documents are material or constitute "prior art." If the Examiner applies any of the documents as prior art against any claim in the application, and applicants determine that the cited documents do not constitute "prior art" under United States law, applicants reserve the right to present to the office the relevant facts and law regarding the appropriate status of such documents.

Applicants further reserve the right to take appropriate action to establish the patentability of the disclosed invention over the listed documents, should one or more of the documents be applied against the claims of the present application.


If there is any fee due in connection with the filing of this Information Disclosure Statement, please charge the fee to our Deposit Account No. 06-0916.

Respectfully submitted,

FINNEGAN, HENDERSON, FARABOW,
GARRETT & DUNNER

Date: November 30, 1994

By


Glenn E. J. Murphy
Reg. No. 33,539